Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Stintzing

Showing results (1-10 of 228) with videos related to

Pageof 23
Sort By:
Deutsche Medizinische Wochenschrift (1946)|October 28, 2017
[Personalized Treatment for Colorectal Carcinomas]Sebastian Stintzing
F1000Prime Reports|January 13, 2015
Management of colorectal cancerSebastian Stintzing
F1000Research|October 23, 2018
Recent advances in understanding colorectal cancerSebastian Stintzing
The Lancet. Oncology|December 8, 2016
A still missing piece of the FIRE-3 puzzle - Authors' replySebastian Stintzing, Volker Heinemann
Cancer Discovery|June 4, 2015
Sym004: Truly a New Level of Anti-EGFR Treatment?Sebastian Stintzing, Volker Heinemann
Deutsche Medizinische Wochenschrift (1946)|November 6, 2021
[Neoadjuvant and adjuvant therapy of resectable colon cancer - Current standards and developments]Volker Heinemann, Sebastian Stintzing
Translational Cancer Research|February 4, 2022
Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?Christoph Schulz, Sebastian Stintzing
The Lancet. Oncology|December 3, 2014
FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' replyVolker Heinemann, Sebastian Stintzing
Radiologie (Heidelberg, Germany)|April 23, 2025
[Molecular testing and liquid biopsies in colorectal cancer]Arndt Stahler, Sebastian Stintzing
European Journal of Cancer (Oxford, England : 1990)|September 20, 2024
Response to letter re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidednessSebastian Stintzing, Takayuki Yoshino
Pageof 23

Showing results (1-10 of 228) with videos related to

Sort By:
Pageof 23
Deutsche Medizinische Wochenschrift (1946)|October 28, 2017
[Personalized Treatment for Colorectal Carcinomas]Sebastian Stintzing
F1000Prime Reports|January 13, 2015
Management of colorectal cancerSebastian Stintzing
F1000Research|October 23, 2018
Recent advances in understanding colorectal cancerSebastian Stintzing
The Lancet. Oncology|December 8, 2016
A still missing piece of the FIRE-3 puzzle - Authors' replySebastian Stintzing, Volker Heinemann
Cancer Discovery|June 4, 2015
Sym004: Truly a New Level of Anti-EGFR Treatment?Sebastian Stintzing, Volker Heinemann
Deutsche Medizinische Wochenschrift (1946)|November 6, 2021
[Neoadjuvant and adjuvant therapy of resectable colon cancer - Current standards and developments]Volker Heinemann, Sebastian Stintzing
Translational Cancer Research|February 4, 2022
Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?Christoph Schulz, Sebastian Stintzing
The Lancet. Oncology|December 3, 2014
FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' replyVolker Heinemann, Sebastian Stintzing
Radiologie (Heidelberg, Germany)|April 23, 2025
[Molecular testing and liquid biopsies in colorectal cancer]Arndt Stahler, Sebastian Stintzing
European Journal of Cancer (Oxford, England : 1990)|September 20, 2024
Response to letter re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidednessSebastian Stintzing, Takayuki Yoshino
Pageof 23